Clinical Trials Logo

Clinical Trial Summary

The Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727 is prepared from human stool from a healthy, screened donor. Requestors will contact the study team about the product (PRIM-DJ2727) by email, visit, or phone call. A screening list for donors will be provided to make sure that the list fits the requestor's requirements. A basic fee will be requested to recover the cost of making the product. After an agreement is made, a contract will be signed between the 2 parties. A week before the treatment, requestors will contact the study team for possible FMT product delivery. Delivery method will be confirmed for delivery by personnel (within 10 minutes driving distance) or by using FedEx services. Each delivered product will have an approved delivery form signed and dated by both the person who prepared the delivery and the person who received the package.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03786900
Study type Expanded Access
Source The University of Texas Health Science Center, Houston
Contact Herbert L DuPont, MD
Phone 713 500 9366
Email herbert.l.dupont@uth.tmc.edu
Status Available
Phase

See also
  Status Clinical Trial Phase
Completed NCT05201079 - Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin Phase 3
Terminated NCT01226992 - Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin Phase 2/Phase 3
Not yet recruiting NCT04960306 - Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection Phase 3
Completed NCT03462459 - Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection Phase 2
Recruiting NCT06237452 - VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3
Recruiting NCT05826418 - Dietary Optimization of Microbiome Recovery Following Fecal Microbiota Transplantation N/A
Completed NCT03497806 - Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiotaâ„¢ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection Phase 2
Suspended NCT01202630 - BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection Phase 3
Terminated NCT03973697 - Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection Phase 2
Completed NCT03353506 - Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection Phase 2
Completed NCT01925417 - Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea Phase 2